F
L. H. Lühning et al.
Letter
Synlett
Schmidtmann, M.; Doye, S. Angew. Chem. Int. Ed. 2014, 53, 7918;
Angew. Chem. 2014, 126, 8052. (k) Dörfler, J.; Preuß, T.; Brahms,
C.; Scheuer, D.; Doye, S. Dalton Trans. 2015, 44, 12149.
(l) Dörfler, J.; Bytyqi, B.; Hüller, S.; Mann, N. M.; Brahms, C.;
Schmidtmann, M.; Doye, S. Adv. Synth. Catal. 2015, 357, 2265.
(m) Lühning, L. H.; Brahms, C.; Nimoth, J. P.; Schmidtmann, M.;
Doye, S. Z. Anorg. Allg. Chem. 2015, 641, 2071. (n) Manßen, M.;
Lauterbach, N.; Dörfler, J.; Schmidtmann, M.; Saak, W.; Doye, S.;
Beckhaus, R. Angew. Chem. Int. Ed. 2015, 54, 4383; Angew. Chem.
2015, 127, 4458. (o) Weers, M.; Lühning, L. H.; Lührs, V.;
Brahms, C.; Doye, S. Chem. Eur. J. 2017, 23, 1237. (p) Lühning, L.
H.; Strehl, J.; Schmidtmann, M.; Doye, S. Chem. Eur. J. 2017, 23,
4197.
(12) General Procedure for the One-Pot Synthesis of 1,4-Ben-
zoazasilines, as Exemplified by the Synthesis of Product 44a
An oven-dried Schlenk tube equipped with a Teflon stopcock
and a magnetic stirring bar was transferred into a nitrogen-
filled glovebox and charged with catalyst III (154 mg, 0.20
mmol, 10 mol%) and toluene (0.5 mL). Afterwards, N-methylani-
line (3, 214 mg, 2.00 mmol), (ortho-bromophenyl)dimethylvi-
nylsilane (37, 531 mg, 2.20 mmol), and toluene (0.5 mL) were
added. After the mixture had been heated to 160 °C for 24 h, the
Schlenk tube was cooled to r.t. and transferred back into a nitro-
gen-filled glovebox. Then Pd2(dba)3 (46 mg, 0.05 mmol, 2.5
mol%), RuPhos (66 mg, 0.1 mmol, 7 mol%), NaOt-Bu (288 mg, 3.0
mmol), and toluene (5 mL) were added. After heating the
mixture to 110 °C for additional 24 h, the crude product was
purified by flash chromatography (SiO2, PE), to give 1,4-ben-
zoazasiline 44a (420 mg, 1.57 mmol, 79%) as a colorless oil. Rf =
0.20 (SiO2, PE). 1H NMR (500 MHz, CDCl3): δ = 7.39 (dd, J= 7.2,
1.5 Hz, 1 H), 7.32 (t, J= 7.9 Hz, 2 H), 7.16 (d, J= 7.5 Hz, 2 H), 7.10–
7.03 (m, 2 H), 6.83 (td, J= 7.2, 0.6 Hz, 1 H), 6.66 (d, J= 8.4 Hz, 1 H),
3.85 (dd, J= 13.1, 3.6 Hz, 1 H), 3.55 (dd, J= 13.1, 9.6 Hz, 1 H),
1.30–1.23 (m, 1 H), 1.04 (d, J= 7.5 Hz, 3 H), 0.28 (s, 3 H), 0.26 (s,
3 H) ppm. 13C{1H} NMR (125 MHz, DEPT, CDCl3): δ = 154.1 (C),
149.6 (C), 135.1 (CH), 129.5 (CH), 129.4 (CH), 124.7 (CH), 123.6
(C), 123.1 (CH), 119.2 (CH), 117.8 (CH), 57.5 (CH2), 17.9 (CH),
13.0 (CH3), –1.7 (CH3), –4.4 (CH3) ppm. 29Si{1H} NMR (99.4 MHz,
INEPT, CDCl3): δ = –8.1 ppm. GC–MS (EI, 70 eV): m/z(%) = 267
(40) [M]+, 225 (100) [C14H15NSi]+, 210 (40), 180 (8), 105 (11)
[C7H7N]+, 91 (5) [C6H5N]+. HRMS (EI): m/z calcd for C17H21NSi:
267.1438; found: 267.1440 [M]+. IR (ATR, neat): λ–1 = 2948,
2864, 1585, 1557, 1494, 1472, 1431, 1340, 1248, 1175, 1129,
(7) Elkin, T.; Kulkarni, N. V.; Tumanskii, B.; Botoshansky, M.;
Shimon, L. J. W.; Eisen, M. S. Organometallics 2013, 32, 6337.
(8) For reviews on the Buchwald-Hartwig amination, see:
(a) Hartwig, J. F. Nature (London, U.K.) 2008, 455, 314. (b) Surry,
D. S.; Buchwald, S. L. Angew. Chem. Int. Ed. 2008, 47, 6338;
Angew. Chem. 2008, 120, 6438. (c) Schlummer, B.; Scholz, U.
Adv. Synth. Catal. 2004, 346, 1599. (d) Elkema, R.; Anderson, H. L.
Macromolecules 2008, 41, 9930.
(9) For reviews on organosilicon compounds with medicinal appli-
cations, see: (a) Mills, J. S.; Showell, G. A. Expert Opin. Invest.
Drugs 2004, 13, 1149. (b) Franz, A. K.; Wilson, S. O. J. Med. Chem.
2013, 56, 388.
(10) (a) Aoyama, T.; Sato, Y.; Suzuki, T.; Shirai, H. J. Organomet. Chem.
1978, 153, 193. (b) Francois, C.; Boddaert, T.; Durandetti, M.;
Querolle, O.; Van Hijfte, L.; Meerpoel, L.; Angibaud, P.;
Maddaluno, J. Org. Lett. 2012, 14, 2074.
(11) Geyer, M.; Karlsson, O.; Baus, J. A.; Wellner, E.; Tacke, R. J. Org.
Chem. 2015, 80, 5804.
1088, 835, 808, 722, 750, 696, 610 cm–1
.
© Georg Thieme Verlag Stuttgart · New York — Synlett 2017, 28, A–F